目的 比較托拉塞米和丹參酮Ⅱ_A磺酸鈉治療慢性充血性心力衰竭的臨床療效。方法 選取2014年1月-2015年12月在邢臺(tái)市第三醫(yī)院治療的慢性充血性心力衰竭患者78例，隨機(jī)分為對(duì)照組和治療組，每組各39例。對(duì)照組靜脈注射丹參酮Ⅱ_A磺酸鈉注射液，20 mg/次，1次/d。治療組靜脈注射托拉塞米注射液，20 mg/次，1次/d。兩組均連續(xù)治療7 d。觀察兩組的臨床療效，比較兩組B型腦鈉肽（BNP）、血漿腎素（PRA）、血管緊張素Ⅱ（AngⅡ）、醛固酮（ALD）和左心室肥厚指標(biāo)。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為69.2%、87.2%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組BNP、PRA、AngⅡ和ALD水平均有明顯下降，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)的下降程度明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組左室后壁舒張末期厚度（LVPWT）、左室舒張末期內(nèi)徑（LVDD）和室間隔舒張末期厚度（IVST）均有明顯下降，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)的下降程度明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 托拉塞米治療慢性充血性心力衰竭的臨床療效優(yōu)于丹參酮Ⅱ_A磺酸鈉，能降低血漿BNP、PRA、AngⅡ和ALD水平，改善左心室肥厚，安全性較好，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To compare the clinical efficacy between torasemide and sulfotanshinone sodium in treatment of chronic congestive heart failure. Methods Patients (78 cases) with chronic congestive heart failure in Xingtai Third Hospital from January 2013 to February 2015 were randomly divided into control and treatment groups, and each group had 39 cases. Patients in the control group were iv administered with Sulfotanshinone Sodium Injection, 20 mg/time, once daily. Patients in the treatment group were iv administered with Torsemide Injection, 20 mg/time, once daily. Patients in two groups were treated for 7 d. After treatment, the clinical efficacies were evaluated, and BNP, PRA, Ang Ⅱ, ALD, and left ventricular hypertrophy indexes in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 69.2% and 87.2%, respectively, and there was difference between two groups (P<0.05). After treatment, the levels of BNP, PRA, Ang Ⅱ, and ALD in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, LVPWT, LVDD and IVST in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion The clinical curative effect of torasemide in treatment of chronic congestive heart failure was better than that of sulfotanshinone Sodium, can decrease the levels of BNP, PRA, Ang Ⅱ, and ALD, and improve left ventricular hypertrophy, with good safety, which has a certain clinical application value.